Melanoma vaccine - Chiron/Duke University
Latest Information Update: 02 Oct 2021
At a glance
- Originator Chiron Technologies
- Developer Chiron Technologies; Nonindustrial source
- Class Cancer vaccines
- Mechanism of Action Immunostimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma